GUGGENHIME ANDREW 4

What Happened Andrew Guggenhime, a director of Caribou Biosciences (CRBU), was granted a derivative award on February 20, 2026 covering 45,000 shares. The Form 4 reports the acquisition price as $0.00 and classifies the transaction as an award/grant (Code A). This is an equity award (option-type) rather than an open-market purchase or sale — no cash changed hands at grant.

Key Details

• Transaction date: 2026-02-20; Transaction type: Grant/Award (Code A); reported acquisition price: $0.00.
• Vesting: One-twelfth of the shares will vest on each monthly anniversary of the grant date; fully vested on February 20, 2027, subject to continued service (Footnote F1).
• Shares owned after transaction: Not disclosed in the materials provided.
• Filing timeliness: Reported on the same date (2026-02-20), indicating a timely Form 4 filing.
• Other notes: The filing identifies the award as a derivative option; the exercise price and other option terms are not shown in the summary.

Context This filing documents an equity award to a director that vests monthly over one year. For retail investors, awards like this are routine compensation for service and do not by themselves indicate immediate buying or selling intent. Because this is a derivative award, any future value to the director will depend on vesting, potential exercise (and exercise price/terms), and any subsequent sales.